Women With Aggressive HER2 Positive Breast Cancer May Miss Out On Chemotherapy And Trastuzumab (Herceptin®)

Women with a particularly aggressive form of early stage (primary) breast cancer may miss out on optimal treatment which may include chemotherapy and trastuzumab (Herceptin) as a result of untimely or missing HER2-status test results, according to doctors responding to the results from a North of England Cancer Network audit of HER2-testing today.

More: continued here

Filed under: Breast Cancer on October 27th, 2008